Market Insight: Health Catalyst Inc (HCAT)’s Notable Drop, Closing at 6.65

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Health Catalyst Inc (NASDAQ: HCAT) closed at $6.65 down -1.92% from its previous closing price of $6.78. In other words, the price has decreased by -$1.92 from its previous closing price. On the day, 0.96 million shares were traded. HCAT stock price reached its highest trading level at $6.68 during the session, while it also had its lowest trading level at $6.37.

Ratios:

For a deeper understanding of Health Catalyst Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.67.

On January 03, 2024, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $11.

On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $14.Barclays initiated its Overweight rating on January 03, 2024, with a $14 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 15 ’24 when Llewelyn Linda sold 2,005 shares for $6.11 per share. The transaction valued at 12,251 led to the insider holds 126,226 shares of the business.

Llewelyn Linda sold 2,005 shares of HCAT for $15,648 on Mar 15 ’24. The Chief People Officer now owns 128,231 shares after completing the transaction at $7.80 per share. On Feb 27 ’24, another insider, Burton Daniel D., who serves as the Chief Executive Officer of the company, bought 26,200 shares for $7.81 each. As a result, the insider paid 204,525 and bolstered with 1,172,623 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 392572768 and an Enterprise Value of 328397184. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.33 while its Price-to-Book (P/B) ratio in mrq is 1.06. Its current Enterprise Value per Revenue stands at 1.11 whereas that against EBITDA is -6.169.

Stock Price History:

The Beta on a monthly basis for HCAT is 1.33, which has changed by -0.31237322 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $14.37, while it has fallen to a 52-week low of $5.45. The 50-Day Moving Average of the stock is -6.31%, while the 200-Day Moving Average is calculated to be -26.95%.

Shares Statistics:

For the past three months, HCAT has traded an average of 649.06K shares per day and 712160 over the past ten days. A total of 58.30M shares are outstanding, with a floating share count of 56.16M. Insiders hold about 4.86% of the company’s shares, while institutions hold 90.02% stake in the company. Shares short for HCAT as of 1713139200 were 1758337 with a Short Ratio of 2.71, compared to 1710460800 on 1822781. Therefore, it implies a Short% of Shares Outstanding of 1758337 and a Short% of Float of 3.04.

Earnings Estimates

Current recommendations for the stock of the company come from 14.0 analysts. On average, analysts expect EPS of $0.03 for the current quarter, with a high estimate of $0.06 and a low estimate of -$0.06, while EPS last year was $0.05. The consensus estimate for the next quarter is $0.08, with high estimates of $0.12 and low estimates of $0.01.

Analysts are recommending an EPS of between $0.45 and -$0.01 for the fiscal current year, implying an average EPS of $0.32. EPS for the following year is $0.5, with 15.0 analysts recommending between $0.65 and $0.35.

Revenue Estimates

A total of 16 analysts believe the company’s revenue will be $74.8M this quarter.It ranges from a high estimate of $75.5M to a low estimate of $74.05M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $71.24MFor the next quarter, 16 analysts are estimating revenue of $75.55M. There is a high estimate of $76.97M for the next quarter, whereas the lowest estimate is $74.59M.

A total of 17 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $311.4M, while the lowest revenue estimate was $306.03M, resulting in an average revenue estimate of $308.68M. In the same quarter a year ago, actual revenue was $295.94MBased on 17 analysts’ estimates, the company’s revenue will be $344.82M in the next fiscal year. The high estimate is $351.98M and the low estimate is $337.8M.

Most Popular